I also suspect that the Nasdaq IPO will be delayed until Q1 2021. Which makes sense as hopefully we are annualising $20m in revenue by then based on what's been announced.
Plus add in FDA for the patch and NMPA for the prizma.
No wonder directors are pushing through these performance shares!!
GMV Price at posting:
6.4¢ Sentiment: Buy Disclosure: Held